G protein-coupled receptor

5-HT2C receptor

5-hydroxytryptamine receptor 2C

The 5-HT2C receptor was first called 5-HT1C. It was described as a serotonin binding site in the choroid plexus of the pig brain, and its cDNA was later cloned from the choroid plexus of the rat. Like the other 5-HT2 receptors, it is a G protein-coupled receptor.1,2,3 It was moved from the 5-HT1 family to the 5-HT2 family once it had been cloned and its characteristics were known. Activation of the receptor increases the activity of phospholipase C in the choroid plexus of several species and in transfected cells, through a G protein.4,5 In cells that carry the human receptor, agonists cause a rapid rise in calcium inside the cell.6

The receptor was first found in the choroid plexus, where it is very abundant and may help to regulate the exchange of ions between the brain and the cerebrospinal fluid. It is also widely distributed in the brain, and its mRNA is very high in the retrosplenial, piriform and entorhinal cortex, the anterior olfactory nucleus, the lateral septal nucleus, the subthalamic nucleus, the amygdala, the subiculum, the lateral habenula, the substantia nigra pars compacta, several brainstem nuclei and the whole grey matter of the spinal cord. The mRNA turned up in more places than the binding sites, and the authors concluded that this is a principal serotonin receptor of the brain. Unlike the 5-HT2A and 5-HT2B receptors, it has little evidence of expression outside the central nervous system.7,8,4 The mRNAs of the 5-HT2A and the 5-HT2C receptor are found in distinct but overlapping sets of regions. Both are high in the anterior olfactory nucleus, the piriform cortex, the endopiriform nucleus, the claustrum, the ventral part of CA3, the substantia nigra pars compacta and several brainstem nuclei. In the caudate-putamen both are present but with different distributions.8

Its messenger RNA is edited in a tissue-specific way, which gives several forms of the receptor. Editing can make the receptor interact 10 to 15 times less efficiently with its G proteins.9

Mice that lack the receptor become overweight because their feeding behaviour is no longer controlled normally, and they are prone to spontaneous, sometimes fatal seizures.3 Later work followed the weight gain of these mice. They eat more food although they respond normally to leptin. Their weight departs from that of normal mice after about 20 weeks of age, and at 42 weeks they are on average 30 percent heavier. Older mutants develop insulin resistance and impaired glucose tolerance, and a high-fat diet leads to high blood glucose without high blood lipids.10 In animal studies all 5-HT2C agonists decrease food intake, while antagonists and inverse agonists can cause weight gain in rodents and humans. In most animal studies selective antagonists did not increase food intake on their own, and they did not cause seizures. The faults of the knockout mice may therefore partly arise during development and not only from the loss of the receptor in the adult.11,7,4

Lorcaserin, a selective 5-HT2C agonist, was developed to lower body weight and was approved in the United States in 2012. In a year-long placebo-controlled trial with 3182 obese or overweight adults, 47.5 percent of those taking lorcaserin lost at least 5 percent of their body weight, against 20.3 percent on placebo, an average of 5.8 kg against 2.2 kg. Valve disease was not more frequent. This mattered because the older drugs fenfluramine and dexfenfluramine had raised the risk of valve disease, an effect thought to come from agonism of the 5-HT2B receptor. The most frequent side effects were headache, dizziness and nausea.12,13 In 2020 the FDA asked the manufacturer to withdraw lorcaserin from the US market. A large postmarketing trial with 12,000 patients, which was not designed to test cancer, showed more cancer diagnoses with lorcaserin than with placebo. The FDA counted 990 cancer diagnoses in 885 patients, and 7.7 percent of the patients on lorcaserin and 7.1 percent on placebo were diagnosed with cancer. Colorectal, pancreatic and lung cancer were notably more frequent with lorcaserin. Combined with other serotonergic drugs, lorcaserin also seems to carry a risk of serotonin syndrome, and its safety in that setting has not been established.13,11

Many antipsychotics, antidepressants and anxiolytics bind to the receptor. Both agonists and antagonists have been proposed for anxiety, depression and schizophrenia, an apparent paradox that the authors of a review link to the animal models used and to the multiple and competing actions of the receptor in the brain. In the case of antipsychotics, blocking the 5-HT2C receptor appears to diminish some of the actions of blocking the 5-HT2A receptor.11,14

Sources (14)
  1. Pazos et al. 1984Pazos A, Hoyer D, Palacios JM (1984) The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site Eur J Pharmacol
  2. Julius et al. 1988Julius D, MacDermott AB, Axel R, et al. (1988) Molecular characterization of a functional cDNA encoding the serotonin 1c receptor Science
  3. Tecott et al. 1995Tecott LH, Sun LM, Akana SF, et al. (1995) Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors Nature
  4. Barnes et al. 1999Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function Neuropharmacology
  5. Barnes et al. 2021Barnes NM, Ahern GP, Becamel C, et al. (2021) International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function Pharmacol Rev
  6. Porter et al. 1999Porter RH, Benwell KR, Lamb H, et al. (1999) Functional characterization of agonists at recombinant human 5-HT2A, 5-HT2B and 5-HT2C receptors in CHO-K1 cells Br J Pharmacol
  7. Nichols et al. 2008Nichols DE, Nichols CD (2008) Serotonin receptors Chem Rev
  8. Pompeiano et al. 1994Pompeiano M, Palacios JM, Mengod G (1994) Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors Brain Res Mol Brain Res
  9. Burns et al. 1997Burns CM, Chu H, Rueter SM, et al. (1997) Regulation of serotonin-2C receptor G-protein coupling by RNA editing Nature
  10. Nonogaki et al. 1998Nonogaki K, Strack AM, Dallman MF, et al. (1998) Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene Nat Med
  11. Di Giovanni et al. 2016Di Giovanni G, De Deurwaerdère P (2016) New therapeutic opportunities for 5-HT2C receptor ligands in neuropsychiatric disorders Pharmacology & Therapeutics
  12. Smith et al. 2010Smith SR, Weissman NJ, Anderson CM, et al. (2010) Multicenter, placebo-controlled trial of lorcaserin for weight management N Engl J Med
  13. Sharretts et al. 2020Sharretts J, Galescu O, Gomatam S, et al. (2020) Cancer Risk Associated with Lorcaserin - The FDA's Review of the CAMELLIA-TIMI 61 Trial N Engl J Med
  14. Meltzer 1999Meltzer HY (1999) The role of serotonin in antipsychotic drug action Neuropsychopharmacology

Binding affinity (Kᵢ)

28 substances, 38 displayed values. Strongest first within each organism. The bar is pKᵢ on a log scale. Open a row to see the assay and every report behind the value.

Human

28 measurements
  • DOBAgonistdepends on assay1.3 nMNelson et al. 1999
    Assay
    cloned human 5-HT2C receptor in AV12 cells; agonist-radioligand [125I]DOI binding
    Shown value from
    Nelson et al. 1999, Table 1
    Error
    ± 0.20 SEM, n = 3

    Values depend on the assay, species or conditions, and each is valid only for its own. 2 reports in all, 1.3–42 nM.

  • DOIAgonistdepends on assay2.4 nMNelson et al. 1999 · 3 reports
    Assay
    cloned human 5-HT2C receptor in AV12 cells; agonist-radioligand [125I]DOI binding
    Shown value from
    Nelson et al. 1999, Table 1
    Range
    2.4–46 nM in 3 reports
    Error
    ± 0.30 SEM, n = 3

    Values depend on the assay, species or conditions, and each is valid only for its own. 4 reports in all, 2.4–46 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Nelson et al. 19992.4 nMTable 1
    Jain et al. 202546 nMTable S4
    Glatfelter et al. 202241 nMTable 1
  • ALD-5210 nMHalberstadt et al. 2020
    Assay
    cloned human 5-HT2C receptor; [3H]mesulergine competition
    Shown value from
    Halberstadt et al. 2020, Table 1
    Error
    ± 3.5 SEM, n = 3
  • DOMAgonistother reports differ19 nMEshleman et al. 2018 · 5 reports
    Assay
    recombinant human 5-HT2C receptor; [125I]DOI competition binding
    Shown value from
    Eshleman et al. 2018, Table 1
    Range
    19–404 nM in 5 reports
    Error
    ± 2.4 SEM, n = 4

    This is the best-supported value. Other reports differ. 6 reports in all, 19–3980 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Luethi et al. 2026404 nMTable 1
    Eshleman et al. 201819 nMTable 1
    Janowsky et al. 201426 nMTable 1
    Jain et al. 2025220 nMTable S4
    Eshleman et al. 201426 nMTable 2
  • 2C-IAgonistdepends on assay40 nMRickli et al. 2015
    Assay
    cloned human receptor (HEK293)
    Shown value from
    Rickli et al. 2015, Table 1
    Error
    ± 9.0 SD

    Values depend on the assay, species or conditions, and each is valid only for its own. 2 reports in all, 10–40 nM.

  • 2C-PAgonist40 nMRickli et al. 2015
    Assay
    cloned human receptor (HEK293)
    Shown value from
    Rickli et al. 2015, Table 1
    Error
    ± 5.0 SD
  • LSDAgonistdepends on assay45 nMHalberstadt et al. 2020 · 6 reports
    Assay
    cloned human 5-HT2C receptor; [3H]mesulergine competition
    Shown value from
    Halberstadt et al. 2020, Table 1
    Range
    1.3–45 nM in 6 reports
    Error
    ± 16 SEM, n = 3

    Values depend on the assay, species or conditions, and each is valid only for its own. 8 reports in all, 1.3–45 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Halberstadt et al. 202045 nMTable 1
    Jain et al. 202517 nMTable S4
    Eshleman et al. 20181.6 nMTable 1
    Janowsky et al. 20142.9 nMTable 1
    Eshleman et al. 20143.2 nMTable 2
    Eshleman et al. 20131.3 nMTable 5
  • 2C-BAgonist47 nMRickli et al. 2015 · 2 reports
    Assay
    cloned human receptor (HEK293)
    Shown value from
    Rickli et al. 2015, Table 1
    Range
    47–90 nM in 2 reports
    Error
    ± 9.0 SD
    Sources and values behind the range, same assay family
    ReportValueWhere
    Ray 201090 nMTable S2 (AllKiData)
    Rickli et al. 201547 nMTable 1
  • ETH-LADAgonist56 nMJain et al. 2025
    Assay
    radioligand competition binding on crude membranes of transfected HEK293T cells (secondary binding assay, radioligand not stated in the paper)
    Shown value from
    Jain et al. 2025, Table S4
  • AL-LADAgonist68 nMJain et al. 2025
    Assay
    radioligand competition binding on crude membranes of transfected HEK293T cells (secondary binding assay, radioligand not stated in the paper)
    Shown value from
    Jain et al. 2025, Table S4
  • 2C-CAgonistdepends on assay90 nMRickli et al. 2015
    Assay
    cloned human receptor (HEK293)
    Shown value from
    Rickli et al. 2015, Table 1
    Error
    ± 26 SD

    Values depend on the assay, species or conditions, and each is valid only for its own. 2 reports in all, 5.4–90 nM.

  • PsilocinAgonistrange incl. untraced94 nMRickli et al. 2016 · 4 reports
    Assay
    HEK293 membranes expressing human 5-HT2C; [3H]mesulergine displacement
    Shown value from
    Rickli et al. 2016, Table 1
    Range
    94–250 nM in 4 reports
    Error
    ± 9.0 SD
    Sources and values behind the range, same assay family
    ReportValueWhere
    Rickli et al. 201694 nMTable 1
    Glatfelter et al. 2022175 nMTable 1
    Jain et al. 2025250 nMTable S4
    Dodd et al. 202394 nMTable 2
  • 2C-EAgonistdepends on assay100 nMRickli et al. 2015 · 2 reports
    Assay
    cloned human receptor (HEK293)
    Shown value from
    Rickli et al. 2015, Table 1
    Range
    100–104 nM in 2 reports
    Error
    ± 20 SD

    Values depend on the assay, species or conditions, and each is valid only for its own. 3 reports in all, 5.4–104 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Ray 2010104 nMTable S2 (AllKiData)
    Rickli et al. 2015100 nMTable 1
  • 2C-DAgonistdepends on assay150 nMRickli et al. 2015
    Assay
    cloned human receptor (HEK293)
    Shown value from
    Rickli et al. 2015, Table 1
    Error
    ± 30 SD

    Values depend on the assay, species or conditions, and each is valid only for its own. 2 reports in all, 13–150 nM.

  • 4-HO-METAgonist153 nMKozell et al. 2023 · 3 reports
    Assay
    human 5-HT2C receptor in HEK-293 cells; [3H]5-HT competition binding
    Shown value from
    Kozell et al. 2023, Table 1
    Range
    141–164 nM in 3 reports
    Error
    ± 43 SEM, n = 3
    Sources and values behind the range, same assay family
    ReportValueWhere
    Rickli et al. 2016141 nMTable 1
    Kozell et al. 2023153 nMTable 1
    Glatfelter et al. 2023164 nMTable 2
  • BufoteninAgonist210 nMJain et al. 2025
    Assay
    radioligand competition binding on crude membranes of transfected HEK293T cells (secondary binding assay, radioligand not stated in the paper)
    Shown value from
    Jain et al. 2025, Table S4
  • DMTAgonistother reports differ234 nMKozell et al. 2023 · 5 reports
    Assay
    human 5-HT2C receptor in HEK-293 cells; [3H]5-HT competition binding
    Shown value from
    Kozell et al. 2023, Table 1
    Range
    111–424 nM in 5 reports
    Error
    ± 16 SEM, n = 22

    This is the best-supported value. Other reports differ. 6 reports in all, 111–424 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Rickli et al. 2016424 nMTable 1
    Kozell et al. 2023234 nMTable 1
    Janowsky et al. 2014166 nMTable 1
    Jain et al. 2025260 nMTable S4
    Eshleman et al. 2014111 nMTable 2
  • 5-MeO-DMTAgonist266 nMGlatfelter et al. 2024 · 2 reports
    Assay
    human 5-HT2C receptor, [3H]mesulergine competition binding
    Shown value from
    Glatfelter et al. 2024, Supplement Figure S1
    Range
    266–490 nM in 2 reports
    Sources and values behind the range, same assay family
    ReportValueWhere
    Jain et al. 2025490 nMTable S4
    Glatfelter et al. 2024266 nMSupplement Figure S1
  • 6-APB270 nMRickli et al. 2015
    Assay
    cloned human 5-HT2C receptor binding
    Shown value from
    Rickli et al. 2015, Table 3
    Error
    ± 50 SD
  • 5-MeO-MiPTAgonist790 nMKozell et al. 2023 · 3 reports
    Assay
    human 5-HT2C receptor in HEK-293 cells; [3H]5-HT competition binding
    Shown value from
    Kozell et al. 2023, Table 1
    Range
    790–1601 nM in 3 reports
    Error
    ± 120 SEM, n = 3
    Sources and values behind the range, same assay family
    ReportValueWhere
    Rickli et al. 20161300 nMTable 1
    Kozell et al. 2023790 nMTable 1
    Glatfelter et al. 20241601 nMSupplement Figure S1
  • PsilocybinAgonistunresolved808 nMGlatfelter et al. 2022 · 2 reports
    Assay
    Transfected-cell radioligand binding at human 5-HT2C (UNC PDSP)
    Shown value from
    Glatfelter et al. 2022, Table 1
    Range
    808–3100 nM in 2 reports

    Reported values disagree and no value is established. 2 reports in all, 808–3100 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Glatfelter et al. 2022808 nMTable 1
    Jain et al. 20253100 nMTable S4
  • 5-APB880 nMRickli et al. 2015
    Assay
    cloned human 5-HT2C receptor binding
    Shown value from
    Rickli et al. 2015, Table 3
    Error
    ± 330 SD
  • MDMAAgonistunresolved1500 nMJain et al. 2025 · 3 reports
    Assay
    radioligand competition binding on crude membranes of transfected HEK293T cells (secondary binding assay, radioligand not stated in the paper)
    Shown value from
    Jain et al. 2025, Table S4
    Range
    1360–9600 nM in 3 reports

    Reported values disagree and no value is established. 3 reports in all, 1360–9600 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Jain et al. 20251500 nMTable S4
    Eshleman et al. 20149600 nMTable 2
    Eshleman et al. 20131360 nMTable 5
  • MDA3000 nMRickli et al. 2015
    Assay
    cloned human 5-HT2C receptor binding
    Shown value from
    Rickli et al. 2015, Table 3
    Error
    ± 900 SD
  • Ephedrine3300 nMRickli et al. 2015
    Assay
    cloned human 5-HT2C receptor binding
    Shown value from
    Rickli et al. 2015, Table 3
    Error
    ± 700 SEM
  • 4-FMA5500 nMRickli et al. 2015
    Assay
    cloned human 5-HT2C receptor binding
    Shown value from
    Rickli et al. 2015, Table 3
    Error
    ± 600 SEM
  • 4-FA7800 nMRickli et al. 2015
    Assay
    cloned human 5-HT2C receptor binding
    Shown value from
    Rickli et al. 2015, Table 3
    Error
    ± 700 SEM
  • Mephedrone9100 nMEshleman et al. 2013
    Assay
    cells expressing human 5-HT2C, [125I]DOI displacement
    Shown value from
    Eshleman et al. 2013, Table 5
    Error
    ± 2100 SEM, n = 4

Pig

2 measurements
  • BufoteninAgonist63 nMColas et al. 1997
    Assay
    pig 5-HT2C receptor expressed in COS-1 cells, [125I]DOI competition binding
    Shown value from
    Colas et al. 1997, Table 1
  • 5-MeO-DMTAgonist100 nMColas et al. 1997
    Assay
    pig 5-HT2C receptor expressed in COS-1 cells, [125I]DOI competition binding
    Shown value from
    Colas et al. 1997, Table 1

Rat

2 measurements
  • PsilocinAgonistsource not traced10 nMDodd et al. 2023
    Assay
    5-HT2C binding, compiled in a review (Table 2), original assay not restated
    Shown value from
    Dodd et al. 2023, Table 2
  • 5-MeO-DMTAgonist418 nMHalberstadt et al. 2012
    Assay
    cloned rat receptor; [3H]mesulergine competition binding (NIMH PDSP)
    Shown value from
    Halberstadt et al. 2012, Table 1
    Error
    ± 35 SEM

Unspecified

6 measurements
  • LSDAgonistrange incl. untraced7.0 nMEgan et al. 2000 · 2 reports
    Assay
    cells stably expressing 5-HT2C, [3H]mesulergine competition (antagonist radioligand, low-affinity state KL)
    Shown value from
    Egan et al. 2000, Table II
    Range
    7.0–12 nM in 2 reports
    Error
    ± 1.5 SEM, n = 3
    Sources and values behind the range, same assay family
    ReportValueWhere
    Egan et al. 20007.0 nMTable II
    Glennon 198712 nMText, section 5 (Ergolines)
  • DOIAgonist60 nMEgan et al. 2000
    Assay
    cells stably expressing 5-HT2C, [3H]mesulergine competition (antagonist radioligand, low-affinity state KL)
    Shown value from
    Egan et al. 2000, Table II
    Error
    ± 5.1 SEM, n = 3
  • PsilocinAgonistsource not traced97 nMDodd et al. 2023
    Assay
    5-HT2C binding, compiled in a review (Table 2), original assay not restated
    Shown value from
    Dodd et al. 2023, Table 2
  • BufoteninAgonistsource not traced145 nMPlazas et al. 2023 · 2 reports
    Assay
    5-HT2C receptor, compiled in a review table (Table 5), original assay not restated
    Shown value from
    Plazas et al. 2023, Table 5
    Range
    70–145 nM in 2 reports
    Sources and values behind the range, same assay family
    ReportValueWhere
    Glennon 198770 nMTable III
    Plazas et al. 2023145 nMTable 5
  • DOBAgonist152 nMEgan et al. 2000
    Assay
    cells stably expressing 5-HT2C, [3H]mesulergine competition (antagonist radioligand, low-affinity state KL)
    Shown value from
    Egan et al. 2000, Table II
    Error
    ± 19 SEM, n = 3
  • DMTAgonist360 nMKeiser et al. 2009
    Assay
    NIMH PDSP radioligand competition binding at the 5-HT2C receptor, [3H]LSD (1.0 nM), standard binding buffer
    Shown value from
    Keiser et al. 2009, Supplementary Table 4

Functional potency (EC₅₀)

19 substances, 29 displayed values. Strongest first within each organism. Emax is shown where the paper reports it. Efficacy depends on the assay and its reference agonist.

Human

18 measurements
  • LSDAgonistdepends on assay1.7 nMEshleman et al. 2018 · 2 reports
    Assay
    recombinant human 5-HT2C receptor; IP-1 formation
    Shown value from
    Eshleman et al. 2018, Table 2
    Range
    0.85–1.7 nM in 2 reports
    Error
    ± 0.29 SEM, n = 3
    Emax
    92.5 ± 4.8%

    Values depend on the assay, species or conditions, and each is valid only for its own. 6 reports in all, 0.85–120 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Eshleman et al. 20181.7 nMTable 2
    Janowsky et al. 20140.85 nMTable 2
  • BufoteninAgonist5.2 nMJain et al. 2025
    Assay
    5-HT2C receptor, calcium flux (FLIPR Tetra) in tetracycline-inducible Flp-In T-REx 293 cells
    Shown value from
    Jain et al. 2025, Table S6
    Emax
    88.4 ± 1.6%
  • DOBAgonistother reports differ7.8 nMPorter et al. 1999
    Assay
    CHO-K1 cells stably expressing recombinant human 5-HT2C VSV isoform; FLIPR calcium mobilization
    Shown value from
    Porter et al. 1999, Table 1
    Emax
    65.0%

    This is the best-supported value. Other reports differ. 5 reports in all, 0.25–66 nM.

  • DOIAgonistother reports differ7.9 nMPorter et al. 1999 · 3 reports
    Assay
    CHO-K1 cells stably expressing recombinant human 5-HT2C VSV isoform; FLIPR calcium mobilization
    Shown value from
    Porter et al. 1999, Table 1
    Range
    6.6–48 nM in 3 reports
    Emax
    57.0%

    This is the best-supported value. Other reports differ. 7 reports in all, 0.14–191 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Porter et al. 19997.9 nMTable 1
    Jain et al. 20256.6 nMTable S6
    Elmore et al. 201848 nMTable 1
  • DOMAgonistunresolved13 nMJain et al. 2025
    Assay
    5-HT2C receptor, calcium flux (FLIPR Tetra) in tetracycline-inducible Flp-In T-REx 293 cells
    Shown value from
    Jain et al. 2025, Table S6
    Emax
    102.2 ± 2.0%

    Reported values disagree and no value is established. 11 reports in all, 0.23–1622 nM.

  • 2C-EAgonistdepends on assay18 nMEshleman et al. 2014 · 4 reports
    Assay
    HEK-h5-HT2C IP-1 formation
    Shown value from
    Eshleman et al. 2014, Table 2
    Range
    0.23–18 nM in 4 reports
    Error
    ± 5.9 SEM
    Emax
    98.0 ± 16.0%

    Values depend on the assay, species or conditions, and each is valid only for its own. 4 reports in all, 0.23–18 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Ray 20100.64 nM, 0.23 nM, 1.1 nMTable S3
    Eshleman et al. 201418 nMTable 2
  • 5-MeO-DMTAgonistunresolved23 nMJain et al. 2025 · 3 reports
    Assay
    5-HT2C receptor, calcium flux (FLIPR Tetra) in tetracycline-inducible Flp-In T-REx 293 cells
    Shown value from
    Jain et al. 2025, Table S6
    Range
    23–64 nM in 3 reports
    Emax
    95.4 ± 1.1%

    Reported values disagree and no value is established. 7 reports in all, 2.6–64 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Cameron et al. 202131 nMExtended Data Fig. 5
    Jain et al. 202523 nMTable S6
    Glatfelter et al. 202464 nMSupplement Figure S4
  • PsilocinAgonistother reports differ34 nMGlatfelter et al. 2022 · 3 reports
    Assay
    cells expressing human 5-HT2C; calcium mobilization
    Shown value from
    Glatfelter et al. 2022, Table 4
    Range
    12–34 nM in 3 reports
    Emax
    84.0%

    This is the best-supported value. Other reports differ. 7 reports in all, 2.0–34 nM.

    Sources and values behind the range, same assay family
    ReportValueWhere
    Klein et al. 202022 nMTable 3
    Glatfelter et al. 202234 nMTable 4
    Jain et al. 202512 nMTable S6
  • 4-HO-METAgonist35 nMKozell et al. 2023
    Assay
    human 5-HT2C receptor in HEK-293 cells; IP-1 formation (Cisbio kit)
    Shown value from
    Kozell et al. 2023, Table 1
    Error
    ± 8.7 SEM, n = 4
    Emax
    100.7 ± 4.9%
  • AL-LADAgonist37 nMJain et al. 2025
    Assay
    5-HT2C receptor, calcium flux (FLIPR Tetra) in tetracycline-inducible Flp-In T-REx 293 cells
    Shown value from
    Jain et al. 2025, Table S6
    Emax
    100.4 ± 32.1%
  • 2C-IAgonistdepends on assay47 nMElmore et al. 2018
    Assay
    HEK293 human 5-HT2C calcium mobilization
    Shown value from
    Elmore et al. 2018, Table 1
    Error
    ± 6.7 SEM
    Emax
    28.0%

    Values depend on the assay, species or conditions, and each is valid only for its own. 4 reports in all, 2.8–540 nM.

  • 2C-DAgonist71 nMEshleman et al. 2014
    Assay
    HEK-h5-HT2C IP-1 formation
    Shown value from
    Eshleman et al. 2014, Table 2
    Error
    ± 8.0 SEM
    Emax
    100.0 ± 14.0%
  • 2C-CAgonistunresolved78 nMElmore et al. 2018
    Assay
    HEK293 human 5-HT2C calcium mobilization
    Shown value from
    Elmore et al. 2018, Table 1
    Error
    ± 5.5 SEM
    Emax
    29.0%

    Reported values disagree and no value is established. 2 reports in all, 24–78 nM.

  • ETH-LADAgonist83 nMJain et al. 2025
    Assay
    5-HT2C receptor, calcium flux (FLIPR Tetra) in tetracycline-inducible Flp-In T-REx 293 cells
    Shown value from
    Jain et al. 2025, Table S6
    Emax
    95.2 ± 1.9%
  • DMTAgonist104 nMKozell et al. 2023 · 2 reports
    Assay
    human 5-HT2C receptor in HEK-293 cells; IP-1 formation (Cisbio kit)
    Shown value from
    Kozell et al. 2023, Table 1
    Range
    96–104 nM in 2 reports
    Error
    ± 11 SEM, n = 20
    Emax
    97.6 ± 2.1%
    Sources and values behind the range, same assay family
    ReportValueWhere
    Kozell et al. 2023104 nMTable 1
    Janowsky et al. 201496 nMTable 2
  • 5-MeO-MiPTAgonistunresolved179 nMKozell et al. 2023
    Assay
    human 5-HT2C receptor in HEK-293 cells; IP-1 formation (Cisbio kit)
    Shown value from
    Kozell et al. 2023, Table 1
    Error
    ± 56 SEM, n = 6
    Emax
    101.2 ± 6.5%

    Reported values disagree and no value is established. 6 reports in all, 2.8–745 nM.

  • MDMAAgonist2500 nMJain et al. 2025
    Assay
    5-HT2C receptor, calcium flux (FLIPR Tetra) in tetracycline-inducible Flp-In T-REx 293 cells
    Shown value from
    Jain et al. 2025, Table S6
    Emax
    34.6 ± 2.8%
  • PsilocybinAgonist3741 nMGlatfelter et al. 2022
    Assay
    cells expressing human 5-HT2C; calcium mobilization
    Shown value from
    Glatfelter et al. 2022, Table 4
    Emax
    88.0%

Mouse

2 measurements
  • PsilocinAgonistsource not traced30 nMPlazas et al. 2023
    Assay
    5-HT2C receptor, compiled in a review table (Table 5), original assay not restated
    Shown value from
    Plazas et al. 2023, Table 5
  • PsilocybinAgonistsource not traced506 nMPlazas et al. 2023
    Assay
    5-HT2C receptor, compiled in a review table (Table 5), original assay not restated
    Shown value from
    Plazas et al. 2023, Table 5

Rat

7 measurements
  • 2C-IAgonist71 nMAcuña-Castillo et al. 2002
    Assay
    rat 5-HT2C receptor in Xenopus laevis oocytes; two-electrode voltage clamp (Cl- current)
    Shown value from
    Acuña-Castillo et al. 2002, Table 3
    Error
    ± 26 SEM, n = 5
    Emax
    44.0 ± 10.0%
  • DOBAgonist102 nMAcuña-Castillo et al. 2002
    Assay
    rat 5-HT2C receptor in Xenopus laevis oocytes; two-electrode voltage clamp (Cl- current)
    Shown value from
    Acuña-Castillo et al. 2002, Table 3
    Error
    ± 26 SEM, n = 6
    Emax
    58.0 ± 3.0%
  • DOIAgonist178 nMAcuña-Castillo et al. 2002
    Assay
    rat 5-HT2C receptor in Xenopus laevis oocytes; two-electrode voltage clamp (Cl- current)
    Shown value from
    Acuña-Castillo et al. 2002, Table 3
    Error
    ± 46 SEM, n = 6
    Emax
    90.0 ± 9.0%
  • DMTAgonist220 nMSmith et al. 1998
    Assay
    Rat choroid plexus, [3H]inositol phosphate formation
    Shown value from
    Smith et al. 1998, Results, Fig. 7
    Emax
    75.0%
  • DOMAgonist423 nMAcuña-Castillo et al. 2002
    Assay
    rat 5-HT2C receptor in Xenopus laevis oocytes; two-electrode voltage clamp (Cl- current)
    Shown value from
    Acuña-Castillo et al. 2002, Table 3
    Error
    ± 209 SEM, n = 5
    Emax
    81.0 ± 13.0%
  • 2C-BAgonist493 nMAcuña-Castillo et al. 2002
    Assay
    rat 5-HT2C receptor in Xenopus laevis oocytes; two-electrode voltage clamp (Cl- current)
    Shown value from
    Acuña-Castillo et al. 2002, Table 3
    Error
    ± 132 SEM, n = 4
    Emax
    50.0 ± 11.0%
  • 2C-DAgonist1308 nMAcuña-Castillo et al. 2002
    Assay
    rat 5-HT2C receptor in Xenopus laevis oocytes; two-electrode voltage clamp (Cl- current)
    Shown value from
    Acuña-Castillo et al. 2002, Table 3
    Error
    ± 793 SEM, n = 5
    Emax
    48.0 ± 7.0%

Unspecified

2 measurements
  • LSDAgonist0.62 nMBasargin et al. 2026
    Assay
    HEK293T cells transiently expressing 5-HT2C with Gαq-RLuc8, human Gβ3 and GFP2-Gγ9, Gq dissociation BRET2
    Shown value from
    Basargin et al. 2026, SI Table S2, p. S19
    Emax
    100.5 ± 4.1%
  • DMTAgonistrange incl. untraced49 nMSmith et al. 1998 · 2 reports
    Assay
    NIH 3T3 fibroblasts expressing the 5-HT2C receptor, [3H]inositol phosphate formation
    Shown value from
    Smith et al. 1998, Results, Fig. 1
    Emax
    85.0%
    Sources and values behind the range, same assay family
    ReportValueWhere
    Cameron et al. 201849 nMTable 2
    Smith et al. 199849 nMResults, Fig. 1

Also reported to act here

Substances reported to act here, without a displayed value.

Values are published numbers in nM per organism. Different assays, species and receptor preparations are not directly interchangeable, and a value does not establish clinical potency or safety.